Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics Inc.May 7, 2019

NEW YORK and CLEVELAND, May 07, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the following upcoming investor conferences.

-- SunTrust Robinson Humphrey 5th Annual Life Science Summit One-on-one Meetings May 8, 2019 Lotte New York Palace, New York, NY

-- 2019 RBC Capital Markets Healthcare Conference Fireside Chat May 22, 2019, 1:35 p.m. ET The InterContinental New York Barclay Hotel, New York, NY

-- Jefferies 2019 Global Healthcare Conference Corporate Presentation June 5, 2019, 2:30 p.m. ET Grand Hyatt, New York, NY

Live webcasts of the fireside chat and corporate presentation will be available on the investor section of the Abeona Therapeutics website, www.abeonatherapeutics.com, and archived replays will be accessible for up to 30 days.

About Abeona TherapeuticsAbeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Company’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB). The Company’s portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM™ AAV vector platform to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two investigational therapies (EB-101 and ABO-102). For more information, visit www.abeonatherapeutics.com.

Investor Contact:Sofia WarnerSenior Director, Investor RelationsAbeona Therapeutics+1 (646) 813-4710 swarner@abeonatherapeutics.com

Media Contact:Scott SantiamoDirector, Corporate CommunicationsAbeona Therapeutics+1 (718) 344-5843 ssantiamo@abeonatherapeutics.com

All contents © copyright 2019 The Associated Press. All rights reserved.